Swedish Orphan Biovitrum AB (publ) (SOBI.ST)

269,00 +6,20 (+2,36%) Al cierre: 05:29PM CEST

Swedish Orphan Biovitrum AB (publ)

Tomtebodavägen 23A
Solna 112 76
Sweden
46 86 97 20 00
https://www.sobi.com

Sector(es): Healthcare
Sector: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 1772

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Guido Oelkers	CEO & President	25,82M	N/A	1965
Mr. Henrik Stenqvist	Chief Financial Officer	N/A	N/A	1967
Mr. Torbjörn Hallberg	General Counsel & Head of Legal Affairs	N/A	N/A	1969
Mr. Daniel Rankin	Head of Strategy & Corporate Development	N/A	N/A	1980
Ms. Lena Bjurner	Head of Human Resources	N/A	N/A	1968
Mr. Armin Reininger M.D., Ph.D.	Senior Scientific & Medical Advisor	N/A	N/A	1957
Mr. Norbert Oppitz	Head of International	N/A	N/A	1967
Mr. Sofiane Fahmy	Head of Europe	N/A	N/A	1972
Mr. Duane H. Barnes	Head of North America	N/A	N/A	1960
Mr. Mahmood Ladha	Head of Strategic Transformation Operations	N/A	N/A	1964

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en SEK.

Descripción

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Sanofi, Apellis Pharmaceuticals Inc., ADC Therapeutics SA, and Cartesian Therapeutics, Inc. Swedish Orphan Biovitrum AB (publ) was incorporated in 1939 and is headquartered in Solna, Sweden.

Gobierno corporativo

El ISS Governance QualityScore de Swedish Orphan Biovitrum AB (publ), a día 1 de abril de 2024, es 2. Las puntuaciones base son Auditoría: 3; Tablero: 4; Derechos de los accionistas: 1; Compensación: 2.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.